Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results Cryoport (NASDAQ: CYRX) reported FY2025 revenue of $176.2 million, up 12% year-over-year and above prior guidance, with Life Sciences Services revenue of $96.5 million (+18%) and Life Sciences Products revenue of $79.7 million (+7%).The company supported a record 760 clinical trials and 20 commercial therapies, ended FY2025 with $411.2 million in cash and provided 2026 revenue guidance of $190.0M–$194.0M (8%–10% growth).

#CYRX Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

www.stocktitan.net/news/CYRX/cryoport-repor...

CEO Jerrell Shelton Sells Some Shares of Cryoport (CYRX) | The Motley Fool

#CYRX #DHLG.Y #3780062e-7d56-4fba-9e5b-10db28ecf0c4 #investing

Origin | Interest | Match

CEO Jerrell Shelton Sells Some Shares of Cryoport (CYRX) | The Motley Fool

#CYRX #DHLG.Y #3780062e-7d56-4fba-9e5b-10db28ecf0c4 #data-news

Origin | Interest | Match

CEO Jerrell Shelton Sells Some Shares of Cryoport (CYRX) | The Motley Fool

#CYRX #DHLG.Y #3780062e-7d56-4fba-9e5b-10db28ecf0c4 #coveragefilings

Origin | Interest | Match

Cryoport's $200M Strategic Move: Sells CRYOPDP to DHL, Launches Game-Changing Healthcare Partnership Cryoport divests courier unit to DHL for $200M while forming strategic alliance. Expands global healthcare logistics capabilities across APAC and EMEA markets. Learn more.

#CYRX Cryoport Completes CRYOPDP Divestiture and Commences Strategic Partnership with DHL Group

www.stocktitan.net/news/CYRX/cryoport-compl...

Cryoport Leans into Strengths as DHL Deal Advances, Cell & Gene Demand Grows, and Tariffs Test Supply Strategy In a macro environment shaped by geopolitical uncertainty, rising tariffs, and uneven biotech sentiment, Cryoport (NASDAQ: CYRX) is leaning into its strengths:

#CYRX
Cryoport reported 10% revenue growth in Q1 2025, driven by strength in Cell & Gene therapy logistics and expanding BioStorage services.
Read the full breakdown:
prismmarketview.com/cryoport-lea...

Cryoport Reports First Quarter 2025 Financial Results Cryoport (NASDAQ: CYRX) reported Q1 2025 revenue of $41.0 million from continuing operations, up 10% year-over-year. The company's commercial Cell & Gene therapy revenue grew 33%, while Life Sciences Services revenue increased 17%. As of March 31, 2025, Cryoport supported 711 global clinical trials, including 79 in Phase 3. The company announced a strategic partnership with DHL, including the planned divestiture of CRYOPDP expected to close in Q2/Q3 2025. Financial highlights include a gross margin of 45.4%, operating costs reduction of 13.7%, and a net loss of $12.0 million ($0.28 per share). The company maintains $244.0 million in cash and investments. For fiscal 2025, Cryoport reiterates revenue guidance of $165.0-172.0 million, representing 5-10% growth.

#CYRX Cryoport Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/CYRX/cryoport-repor...

Major Healthcare Logistics Shake-Up: DHL Acquires CRYOPDP, Targets $5B+ Revenue Strategic acquisition adds 600,000 annual specialized pharma shipments to DHL's portfolio, expanding clinical trials and cell therapy logistics across 135 countries.

#CYRX DHL Group acquires CRYOPDP from Cryoport to strengthen "DHL Health Logistics"

www.stocktitan.net/news/CYRX/dhl-group-acqu...

Game-Changing Cryogenic Freezer Stores 22,000 Samples in Breakthrough Design Advanced -190°C storage system offers unprecedented capacity of 22,000 straws with ergonomic design. Revolutionary solution for fertility clinics and biorepositories.

#CYRX Cryoport's MVE Biological Solutions Expands High-Efficiency Cryogenic Freezer Series With Answer to Evolving Needs of Fertility Clinics, Biorepositories and Clinical Laboratories

www.stocktitan.net/news/CYRX/cryoport-s-mve...

Cryoport Announces Strong Fourth Quarter and Full Year Financial Results for 2024 Cryoport, Inc. has reported impressive financial results for FY 2024, demonstrating strong growth in cell and gene therapy while enhancing margins.

Cryoport Announces Strong Fourth Quarter and Full Year Financial Results for 2024 #United_States #Nashville #Life_Sciences #CryoPort #CYRX

Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results Cryoport (NASDAQ: CYRX) reported its Q4 and FY 2024 financial results, achieving full-year revenue of $228.4 million, aligned with guidance. The company's Commercial Cell & Gene Therapy revenue grew 20% year-over-year to $26 million in FY 2024.Key highlights include supporting 701 global clinical trials, improved gross margin to 45.8% in Q4 2024 (up from 40.6% in Q4 2023), and BioStorage/BioServices revenue growth of 11% in FY 2024. The company added five new approved therapies in 2024, bringing their total commercial therapy count to 19.Financial results show a net loss of $114.8 million for FY 2024, with negative adjusted EBITDA of $15.1 million. The company maintains a strong cash position of $261.7 million and has provided 2025 revenue guidance of $240-250 million.

#CYRX Cryoport Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/CYRX/cryoport-repor...

Cryoport Unveils Revolutionary HV3 Shipping System for Biologics Transport on Narrow Aircraft New Cryoport Express® HV3 system enables -150°C transport on narrow-bodied aircraft, featuring enhanced payload protection and monitoring for vital cell therapies delivery.

#CYRX Cryoport Unveils State-of-the-Art Cryogenic Shipping System for Transporting Lifesaving Biologics and Temperature-Sensitive Therapies

www.stocktitan.net/news/CYRX/cryoport-unvei...

Cryoport Partners with Moffitt Cancer Center for Advanced Biorepository Services in $97B Market CRYOGENE to provide cutting-edge biostorage facilities at Moffitt's Speros FL campus, supporting cell and gene therapy development in rapidly expanding market.

#CYRX Moffitt Cancer Center and Cryoport Announce Strategic Collaboration

www.stocktitan.net/news/CYRX/moffitt-cancer...

Cryoport's MVE Achieves Major FDA Registration Milestone for Global Manufacturing Sites MVE Biological Solutions secures FDA registration for all three manufacturing facilities and product listings, enhancing its position in cryogenic freezer manufacturing worldwide.

#CYRX Cryoport's MVE Biological Solutions Registers All Manufacturing Facilities with the U.S. Food and Drug Administration ("FDA")

www.stocktitan.net/news/CYRX/cryoport-s-mve...

Just In: ( NASDAQ: #CYRX ) VGXI Selects Cryoport for Biostorage, Bioservices and Supply Chain Solutions to Advance Next-Generation Therapies

#StockMarket #News